SALT LAKE CITY(BUSINESS WIRE)
Medical, Inc. has announced that it has received U.S. Food and Drug
Administration (FDA) approval to begin Phase 1 human clinical studies of Natural
Vascular Scaffolding (NVS)?, its novel combination drug/device
therapy for the treatment of peripheral vascular disease (PVD). Alucent
Medical, Inc. is a new company formed to develop and market this novel
photo-activated drug therapy, and is owned by the research and
development arm of Avera Health, an integrated, multi-state health
system based in Sioux Falls, S.D.
The promise of this novel therapy is extraordinary. We believe NVS
could deliver quantum advancement in the treatment of peripheral
vascular disease with the potential of eliminating vascular stents for
this condition, said James Corbett, who is chairman of the board of
Alucent and has 30 years of experience in the medical device field.
The existing standard of care for peripheral vascular disease utilizes
percutaneous balloon angioplasty (PTA), in which balloons are coated
with known antiproliferative drugs such as paclitaxel, and metallic
stents. These treatments often result in recurrence of the target lesion
and the need for retreatment. NVS, in contrast, is a novel
photo-activated drug therapy designed to build natural scaffolding to
keep the vessel open durably, possibly replacing the need for an
NVS has the potential to leap-frog current treatments for peripheral
vascular disease, said Myles Greenberg, MD, president and CEO of
Alucent Medical, Inc.
Phase I studies of NVS will commence this summer at three locations
across the U.S. The principal investigator for the Alucent-sponsored
Phase I trial of NVS therapy in PVD is Gary Ansel, MD, FACC, System
Medical Chief, Vascular Program, OhioHealth, Columbus, Ohio.
We are thrilled that this innovation has reached the point of U.S.
clinical trials. We believe it will improve quality of life for many
patients, and this ultimately is the Avera mission. Weve been behind it
by supporting and investing in this research, and it is extremely
exciting to reach this milestone, said Fred Slunecka, Chief Operating
Officer for Avera Health.
NVS was developed by Avera scientists, and Avera has invested more than
$20 million toward its development. The initial discovery team was led
by founder Ron Utecht, PhD, a former professor of chemistry and
biochemistry at South Dakota State University. Utecht and Avera hold
approximately 20 patents for NVS.
About Avera Health
The Avera Health system, based in Sioux Falls, S.D., has over 17,000
employees and physicians, serving more than 300 locations and 100
communities in a five-state region. Our ministry, our people and our
superior value distinguish Avera. We carry on the health care legacy of
the Benedictine and Presentation Sisters, delivering care in an
environment guided by our values of compassion, hospitality and
stewardship. For more information about Avera, see our website at
About Alucent Medical, Inc.
Alucent Medical, Inc. is a privately held biotechnology company
headquartered in Salt Lake City, Utah. Alucent Medical was founded by
Avera Health to develop and market Natural Vascular Scaffolding (NVS), a
novel combination drug-device product for the treatment of patients
suffering from peripheral vascular disease. Alucent Medical is currently
conducting U.S. Phase 1 human clinical trials. Visit alucentmedical.com
for more information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005429/en/
Nobles Global Communications
Diana Soltesz, 818-618-5634
Source: Alucent Medical, Inc.